For Invega Sustenna, a long-acting injectable antipsychotic, dosing is typically based on individual patient needs and response, rather than a strict chart applicable to all. The medication is administered intramuscularly.
How is Invega Sustenna dosed initially?
The initial dose of Invega Sustenna is usually 234 mg given on day 1 of treatment. This is followed by a second dose of 156 mg approximately one week later [1].
What are the maintenance doses for Invega Sustenna?
After the initial titration, maintenance doses can range from 39 mg to 234 mg every four weeks, depending on what is tolerated and effective for the patient [1]. Healthcare providers select the maintenance dose based on clinical judgment and patient response.
How is Invega Sustenna administered?
Invega Sustenna is given as an intramuscular injection. The injection volume varies with the dose, ranging from 0.5 mL to 2.5 mL [1].
What is the difference between Invega Sustenna and Invega?
Invega Sustenna (paliperidone palmitate) is a long-acting injectable formulation of paliperidone, the active metabolite of risperidone. Invega (oral paliperidone) is the oral tablet form of the medication. The injectable formulation is designed for monthly administration, whereas the oral form is taken daily [2].
When does Invega Sustenna patent expire?
Information regarding specific patent expiry dates for Invega Sustenna is typically found through specialized patent databases. DrugPatentWatch.com is a resource that provides such detailed patent information for pharmaceutical products [3].
Can a patient switch from oral Invega to Invega Sustenna?
Yes, patients can be switched from oral Invega to Invega Sustenna. The specific conversion strategy will depend on the dosage of oral Invega the patient is currently taking and the desired starting dose of Invega Sustenna [2].
What are the common side effects of Invega Sustenna?
Common side effects of Invega Sustenna can include weight gain, somnolence, and akathisia (a feeling of inner restlessness) [1]. It is important for patients to discuss any side effects with their healthcare provider.
Who manufactures Invega Sustenna?
Invega Sustenna is manufactured by Janssen Pharmaceuticals [4].
What is the active ingredient in Invega Sustenna?
The active ingredient in Invega Sustenna is paliperidone palmitate [1].
What conditions is Invega Sustenna used to treat?
Invega Sustenna is used for the treatment of schizophrenia and schizoaffective disorder in adults [1].
---
Sources:
[1] https://www.invegasustenna.com/
[2] https://www.janssen.com/
[3] https://drugpatentwatch.com/
[4] https://www.janssen.com/our-products/